Guggenheim reiterates buy rating on EyePoint Pharmaceuticals

ru.investing.com (Russian)

Guggenheim maintains a "buy" rating on EyePoint Pharmaceuticals (EYPT) stock, citing positive clinical trial progress. The firm set a $68 price target, with trials for macular degeneration and diabetic macular edema showing promising safety and enrollment. EYPT shares have seen significant gains over the past year, despite recent financial results missing expectations.


With a significance score of 1, this news ranks in the top 62% of today's 31434 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Guggenheim reiterates buy rating on EyePoint Pharmaceuticals | News Minimalist